title: Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity.
abstract: This crossover, double-blind study investigated the effects of single oral doses of the prodrug loperamide oxide, which is reduced gradually to loperamide in the intestine, and loperamide on jejunal motor activity in 12 fasting healthy men. Five minutes after a phase III of the migrating motor complex (MMC), 2 mg loperamide oxide, 4 mg loperamide oxide, 4 mg loperamide, or placebo were administered. Thereafter, motor activity 10-30 cm abroad the ligament of Treitz was recorded with five catheter orifices at 3-cm intervals over 4 hr. Number of contractions and area under curve increased significantly with 4 mg loperamide and 4 mg loperamide oxide, the increases with loperamide oxide occurring more gradually. Placebo and 2 mg loperamide oxide had no discernible effects. With both 4 mg loperamide and 4 mg loperamide oxide, phase I of the MMC was slightly prolonged and phase II and the time from drug administration to the onset of the first phase III slightly shortened. The percentage of aborally propagated contractions in phase II increased with all active treatments, whereas the occurrence of phases III was not altered.
authors.affiliation: Psychophysiology Unit, University of Vienna, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Stacher
authors.forename: H
authors.initials: H
authors.lastname: Steinringer
authors.forename: C
authors.initials: C
authors.lastname: Schneider
authors.forename: G V
authors.initials: GV
authors.lastname: Vacariu-Granser
authors.forename: F
authors.initials: F
authors.lastname: Castiglione
authors.forename: G
authors.initials: G
authors.lastname: Gaupmann
authors.forename: U
authors.initials: U
authors.lastname: Weber
authors.forename: G
authors.initials: G
authors.lastname: Stacher-Janotta
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007583:Jejunum / Q000502:physiology*; D008139:Loperamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D011355:Prodrugs / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D011355:Prodrugs; D008139:Loperamide; C066043:loperamide oxide